<DOC>
	<DOCNO>NCT01838967</DOCNO>
	<brief_summary>The investigator investigate potential pharmacokinetic drug-drug interaction Cilnidipine 10 mg Valsartan 160 mg healthy male volunteer receive Cilnidipine 10 mg alone , Valsartan 160 mg , together 3 period repeatedly .</brief_summary>
	<brief_title>A Drug Interaction Study Cilnidipine Valsartan</brief_title>
	<detailed_description>To evaluate safety , drug-tolerance , pharmacokinetics Cilnidipine 10 mg Valsartan 160 mg monotherapy Cilnidipine 10 mg Valsartan 160 mg combination healthy male subject .</detailed_description>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Cilnidipine</mesh_term>
	<criteria>1 . Healthy male volunteer , age 20 40 year 2 . The result Body Mass Index ( BMI ) less 18.5 kg/m2 , 25 kg/m2 body weight least 55 kg 3 . Subjects congenital chronic disease abnormal symptom opinion 4 . Acceptable serum test , hematologic test , blood chemistry examination , urin test ECG , physical examination screen 5 . Subjects ability comprehend objective , content study property study drug participate trial willingness sign inform consent write 1 . A subject clinical evidence history hepatic ( include carrier hepatitis virus ) , renal , respiratory , endocrine , neurologic , immunologic , hematologic , oncologic , psychiatric , cardiovascular disease 2 . A subject history gastrointestinal disease surgery ( except simple appendectomy repair hernia ) , influence absorption study drug 3 . A subject history drug allergy ( aspirin , antibiotic , include study drug etc . ) , history clinically significant allergy 4 . Systolic blood pressure &lt; 100mmHg Diastolic blood pressure &lt; 60 mmHg , systolic blood pressure ≥ 150 mmHg diastolic blood pressure ≥ 100mmHg ( Sitting blood pressure ) screening procedure . 5 . Presence history drug abuse positive result urine drug screen test 6 . Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use OTC medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) 7 . Participation clinical trial drug within 60 day prior participation study 8 . Blood donation 2 month apheresis 1 month study 9 . Use alcohol 21 units/weeks 10 . Smoker smoke 20 cigarette per day 11 . A subject take grapefruit , grapefruit juice , grapefruitcontaining product within 3 day prior participation study 12 . A subject take St John 's wort food include ingredient within 14 day prior participation study 13 . Judged inappropriate study investigator review clinical laboratory result reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>cilnidipin valsartn</keyword>
	<keyword>pharmacokinetic drug drug interaction</keyword>
	<keyword>oral administration</keyword>
	<keyword>healthy male subject</keyword>
</DOC>